Recruiting
B-cell small lymphocytic lymphoma refractory+1
RecruitingRegistered drugNo placebo
Study of sonrotoclax plus obinutuzumab or rituximab compared to venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia
Registered drugNo placebo
- Disease:B-cell small lymphocytic lymphoma refractoryB-cell small lymphocytic lymphoma recurrent
- Substances:ObinutuzumabRituximab+2
Countries:
The Netherlands
The Netherlands- Participants:18–64 years · 65+ years
- Substances:Obinutuzumab
